Trade Sarepta Therapeutics, Inc. - SRPT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.28 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 147.92 |
| Open | 147.12 |
| 1-Year Change | 41.39% |
| Day's Range | 143.51 - 147.12 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 147.45 | 1.41 | 0.97% | 146.04 | 149.62 | 145.87 |
| Jul 24, 2024 | 145.95 | 0.61 | 0.42% | 145.34 | 147.46 | 144.57 |
| Jul 23, 2024 | 147.52 | 1.76 | 1.21% | 145.76 | 148.84 | 144.79 |
| Jul 22, 2024 | 146.28 | 2.55 | 1.77% | 143.73 | 147.17 | 143.59 |
| Jul 19, 2024 | 145.47 | 2.08 | 1.45% | 143.39 | 147.03 | 143.39 |
| Jul 18, 2024 | 143.58 | -3.37 | -2.29% | 146.95 | 147.19 | 143.42 |
| Jul 17, 2024 | 146.14 | -0.72 | -0.49% | 146.86 | 148.96 | 144.56 |
| Jul 16, 2024 | 148.80 | -2.56 | -1.69% | 151.36 | 153.04 | 147.86 |
| Jul 15, 2024 | 152.52 | 1.06 | 0.70% | 151.46 | 153.76 | 149.93 |
| Jul 12, 2024 | 151.97 | -0.20 | -0.13% | 152.17 | 152.62 | 150.11 |
| Jul 11, 2024 | 151.32 | 1.97 | 1.32% | 149.35 | 152.61 | 147.82 |
| Jul 10, 2024 | 149.09 | 0.11 | 0.07% | 148.98 | 151.96 | 148.42 |
| Jul 9, 2024 | 150.12 | 0.60 | 0.40% | 149.52 | 151.95 | 148.11 |
| Jul 8, 2024 | 151.37 | 0.31 | 0.21% | 151.06 | 154.41 | 150.14 |
| Jul 5, 2024 | 151.59 | -0.91 | -0.60% | 152.50 | 152.50 | 150.36 |
| Jul 3, 2024 | 152.36 | -1.42 | -0.92% | 153.78 | 154.88 | 151.05 |
| Jul 2, 2024 | 154.08 | -0.60 | -0.39% | 154.68 | 156.36 | 153.23 |
| Jul 1, 2024 | 155.92 | -0.96 | -0.61% | 156.88 | 162.58 | 155.13 |
| Jun 28, 2024 | 157.83 | 1.01 | 0.64% | 156.82 | 159.63 | 155.63 |
| Jun 27, 2024 | 157.74 | 2.38 | 1.53% | 155.36 | 158.54 | 152.20 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sarepta Company profile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com